BerandaIONS • BMV
add
Ionis Pharmaceuticals Inc
Tutup sebelumnya
$647,00
Rentang tahun
$619,00 - $900,00
Kapitalisasi pasar
6,58 M USD
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 131,61 jt | 10,14% |
Biaya operasional | 83,55 jt | 39,85% |
Laba bersih | -146,94 jt | -2,90% |
Margin laba bersih | -111,64 | 6,58% |
Penghasilan per saham | -0,92 | -20,52% |
EBITDA | -144,05 jt | 1,56% |
Tarif pajak efektif | -0,08% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,15 M | -3,00% |
Total aset | 2,81 M | 1,77% |
Total liabilitas | 2,34 M | -5,28% |
Total ekuitas | 475,73 jt | — |
Saham yang beredar | 159,16 jt | — |
Harga terhadap nilai buku | 216,39 | — |
Tingkat pengembalian aset | -12,62% | — |
Tingkat pengembalian modal | -14,71% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -146,94 jt | -2,90% |
Kas dari operasi | -150,78 jt | -0,56% |
Kas dari investasi | 170,46 jt | 123,98% |
Kas dari pembiayaan | 2,20 jt | -90,67% |
Perubahan kas bersih | 22,12 jt | 143,90% |
Arus kas bebas | -107,97 jt | -16,56% |
Tentang
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Didirikan
1989
Kantor pusat
Situs
Karyawan
1.069
